Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
CBA Posts Record A$10.98B Profit Despite Cautious Outlook 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Add as a preferred source on Google
SK bioscience, a South Korean pharmaceutical firm, announced on Thursday, March 21, that it has exported its influenza vaccine to Thailand. The company developed a cell-cultured influenza vaccine, and after securing the required approvals and permits, it started exporting its Sky Cellflu to the country.
First Batch of Deliveries
According to The Korea Herald, SK Bioscience has already completed the first delivery, which consists of 440,000 doses of the Sky Cellflu vaccine. The products were handed over to its local partner, Biogenetech.
The Korean pharmaceutical company expects to receive more orders and expand its sales once the new influenza vaccine is distributed in Thailand. The deal also marks SK Bioscience's expansion in the Southeast Asian market and entry into the Southern space.
Timely Arrival of the Flu Vaccines
Korea IT Times reported that Thailand has been affected by flu strains, and vaccination is being sought to prevent infections. SK bioscience's Sky Cellflu was also approved by the World Health Organization (WHO) for use in the country.
Moreover, this export is expected to become an excellent example of proper vaccination to combat influenza. Meanwhile, Sky Cellflu already secured proper licenses for distribution in 12 countries, including Malaysia, Thailand, Chile, Singapore, Mongolia, and Pakistan.
World's First Cell Culture-Based Flu Vaccine
SK bioscience's SKYCellflu is said to be the first cell culture-based influenza vaccine in the world. It obtained WHO Pre-qualification (PQ) certification for safe usage and dissemination worldwide.
"The export of SKYCellflu to Thailand serves as a stepping-stone for entering the Southeast Asian and Southern Hemisphere markets and expanding into the global market," SK bioscience's chief executive officer, Ahn Jae Yong, said in a press release. "In addition to diversifying our existing product markets, we are committed to developing vaccines with blockbuster potential, such as our next-generation pneumococcal conjugate vaccine candidate, which is expected to enter phase III clinical trials this year."
Photo by: SK Bioscience Press Release
